AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05683054 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Venapuncture
Description: Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of adalimumab
Study NCT05683054 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dermatology Life Quality Index (DLQI)
Description: The impact of the disease on the patient will be assessed using the dermatology life quality index (DLQI).
Study NCT05683054 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EQ-5D-5L questionnaire
Description: The EQ-5D-5L which is a standardized instrument developed by the EuroQol Group as a measure of health-related quality of life that can be used in a wide range of health conditions and treatments will be assessed.
Study NCT05683054 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dried blood spot sampling
Description: A subset of patients will sample additionally by using dried blood sampling after the first drug injection post-inclusion.
Study NCT00755287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: starting dose 10 IU daily
Study NCT00755287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: As prescribed
Study NCT00755287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: As prescribed
Study NCT00755287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taspoglutide
Description: 10 mg once weekly
Study NCT00755287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taspoglutide
Description: 20 mg once weekly (after 4 weeks of taspoglutide 10 mg once weekly)
Study NCT03744923 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transmuscular QL block
Description: Ultrasound device will be used; The probe is placed in the mid-axillary line cranially to the iliac crest to identify the three muscles of the anterior abdominal wall. Then, scan dorsally keeping the transverse orientation until observing that the transversusabdominus muscle becomes aponeurotic, and this aponeurosis is followed until the QL muscle is clearly visualized with its attachment to the lateral edge of the transverse process of the L2 vertebral body and visualize the thoracolumbar fascia at the lateral edge of the QL muscle.~The view of the psoas major muscle (PM) anteriorly, the erector spinae muscle (ESM) posteriorly and the QL muscle adherent to the apex of the transverse process result in a well recognizable pattern of a Shamrock with three leaves (trifoliate).
Study NCT01958385 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet and Exercise
Description: A structured diet and exercise plan
Study NCT02736188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aceneuramic Acid Extended-Release Tablets
Study NCT03744923 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus Abdominus Plane block
Description: Posterior TAP block will be performed on the same side of surgery (unilateral) under ultrasonographic guidance with a with broadband (7-13MHz) linear probe covered with a sterile plastic sheath. Probe will positioned transversely midway between the iliac crest and the costal margin at level of mid axillary line.~Once the external oblique muscle (EOM), internal oblique muscle (IOM) and transversus abdominis muscle (TAM) are visualized at the level of the mid axillary line between the 12th rib and the iliac crest, the puncture area and the ultrasound probe were prepared in a sterile manner. After identification of the neuro-facial plane between IOM and TAM, block was performed with 20G spinal needle. The needle will be directed to approach the TAP with in-plane USG-guided technique. Once the tip of the needle placed in the space between the IOM and TAM, Inject a 1 ml test dose of lidocaine 2% for hydrovisualization of needle-tip position and confirming its correct postioning.
Study NCT00403793 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etonogestrel with testosterone undecanoate
Description: 42 or 44 weeks with etonogestrel implant and testosterone undecanoate injections every 10 to 12 weeks
Study NCT00403793 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 42 or 44 weeks with placebo implant and placebo injections
Study NCT02010554 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Education
Description: Give patients a pamphlet discussing pros and cons of disease modifying therapies
Study NCT02010554 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Education
Description: Give patients a pamphlet discussing pros and cons of disease modifying therapies
Study NCT02010554 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing-Cognitive Behavioral Therapy
Description: A telephone based talk therapy discussing pros and cons of medication use in MS.
Study NCT00452010 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CEFAR PRIMO TENS Class IIA (active)
Description: Active TENS. 4 sessions per day during 3 months.
Study NCT00452010 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: CEFAR PRIMO TENS Class IIA (no active)
Description: Placebo TENS. 4 sessions per day during 3 months.
Study NCT03487029 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short duration
Description: exercise Short duration high intensity training
Study NCT03487029 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Long duration
Description: exercise Long duration high intensity training
Study NCT02107482 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Levia Narrow Band UVB
Description: The device's spectral output is is Narrow Band UVB (NB-UVB) (NB-Levia): 308-312 nm
Study NCT02107482 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Levia sham/visible-light source
Description: the light spectrum is in the range of 400-700nm, the light is produced using the same Levia® device. Levia® enable the user to switch off the UVB light and only produce visible light spectrum.
Study NCT02747537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Study NCT02747537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Study NCT01953120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept
Description: Subjects will receive intravenous belatacept at 5mg/kg every other week starting from day 1 and continuing with weeks 2, 4, 6, and 8, and then monthly at months 3, 4, 5, and 6. At month 6 patients may elect to continue for an additional six-month period of belatacept administration.
Study NCT03935906 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reach Pathway
Description: Trial of outreach nurse offering point-of-care Hepatitis C (HCV) testing to opiate substitution therapy patients in community pharmacies, which is hypothesised to improve number of patients tested and cured of HCV.
Study NCT03935906 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education-only Pathway
Description: Trial of community pharmacists advising opiate substitution therapy patients to attend a local blood-borne virus clinic to be tested for Hepatitis C by a specialist nurse, which represents the standard care pathway for HCV patients in the countries included in the study.
Study NCT03772275 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: New york Heart Association Class II-IV
Description: New york Heart Association Class II-IV  study of markers
Study NCT03772275 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: New york Heart Association Class I
Description: New york Heart Association Class I
Study NCT01868685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYM338
Description: BYM338
Study NCT01868685 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03403595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-EB-PSMA-617
Description: accepted intravenous injection of 177Lu-EB-PSMA-617 and monitored at 2, 24, 72, 120 and 168 hours post-injection.
Study NCT03774511 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-Intensity Interval Exercise & Moderate Intensity Interval Exercise
Description: Different Interval intensities Exercise
Study NCT02297074 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ordinary white bread
Description: The evening before the test day, subjects consumed a standardised dinner. Volunteers arrived in a 12-h fasting state. A fasting blood sample was acquired after the resting time, and appetite feelings were assessed by using visual analogue The subjects were instructed to consume the tested bread or 50 g of glucose. The subjects immediately completed two VAS, one on appetite feelings and another on bread palatability. The appetite feeling VAS were repeated every 30 min until a total of 180 min had passed. The subjects were not allowed to eat or drink anything else during the 180 min of the intervention.~After the last blood extraction (3 h), an ad libitum lunch and 300 ml of water was provided. Volunteers ate until comfortably satisfied and the amount of food intake was registered
Study NCT02297074 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Precooked-Frozen White Bread
Description: The evening before the test day, subjects consumed a standardised dinner. Volunteers arrived in a 12-h fasting state. A fasting blood sample was acquired after the resting time, and appetite feelings were assessed by using visual analogue The subjects were instructed to consume the tested bread or 50 g of glucose. The subjects immediately completed two VAS, one on appetite feelings and another on bread palatability. The appetite feeling VAS were repeated every 30 min until a total of 180 min had passed. The subjects were not allowed to eat or drink anything else during the 180 min of the intervention.~After the last blood extraction (3 h), an ad libitum lunch and 300 ml of water was provided. Volunteers ate until comfortably satisfied and the amount of food intake was registered
Study NCT03690466 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Study device treatment
Description: The ultrasound portable device comprises a tabletop control unit and a transducer connected to the control unit by a cord.
Study NCT03690466 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham device treatment
Description: A similar device as used for the study device treatment will be used, except that no energy will be delivered to the spleen.
Study NCT02916576 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood-Glucose Monitoring Systems for self-testing
Description: This is a user performance study, that is intended to show whether people with diabetes are able to obtain accurate measurement results with a blood glucose monitoring system (BGMS).~The subjects' measurement technique (e.g. applying blood onto the system reagent, reading the result) will be observed and documented by study personnel.~Immediately after the measurement by the subject, the study personnel will perform a measurement with the same test meter.~Measurement results obtained by the subjects with the BGMS will be compared to measurement results obtained with the comparison method.~Sample collection for the comparison measurement will be performed by study personnel within 5 min after the subject's measurement with the test meter.~The samples will be collected from the subjects' skin puncture (if possible), an additional skin puncture (if required) will be documented.~An additional skin puncture will be performed by study personnel with single-use lancing devices.
Study NCT01703598 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: Placement of Deep Brain Stimulation electrodes
Study NCT01703598 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DBS surgery
Description: Placement of DBS electrodes
Study NCT02064283 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diffusion MRI
Study NCT02297074 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Candeal-flour White Bread
Description: The evening before the test day, subjects consumed a standardised dinner. Volunteers arrived in a 12-h fasting state. A fasting blood sample was acquired after the resting time, and appetite feelings were assessed by using visual analogue The subjects were instructed to consume the tested bread or 50 g of glucose. The subjects immediately completed two VAS, one on appetite feelings and another on bread palatability. The appetite feeling VAS were repeated every 30 min until a total of 180 min had passed. The subjects were not allowed to eat or drink anything else during the 180 min of the intervention.~After the last blood extraction (3 h), an ad libitum lunch and 300 ml of water was provided. Volunteers ate until comfortably satisfied and the amount of food intake was registered
Study NCT02297074 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alfacar White Bread
Description: The evening before the test day, subjects consumed a standardised dinner. Volunteers arrived in a 12-h fasting state. A fasting blood sample was acquired after the resting time, and appetite feelings were assessed by using visual analogue The subjects were instructed to consume the tested bread or 50 g of glucose. The subjects immediately completed two VAS, one on appetite feelings and another on bread palatability. The appetite feeling VAS were repeated every 30 min until a total of 180 min had passed. The subjects were not allowed to eat or drink anything else during the 180 min of the intervention.~After the last blood extraction (3 h), an ad libitum lunch and 300 ml of water was provided. Volunteers ate until comfortably satisfied and the amount of food intake was registered
Study NCT02297074 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wholemeal Bread
Description: The evening before the test day, subjects consumed a standardised dinner. Volunteers arrived in a 12-h fasting state. A fasting blood sample was acquired after the resting time, and appetite feelings were assessed by using visual analogue The subjects were instructed to consume the tested bread or 50 g of glucose. The subjects immediately completed two VAS, one on appetite feelings and another on bread palatability. The appetite feeling VAS were repeated every 30 min until a total of 180 min had passed. The subjects were not allowed to eat or drink anything else during the 180 min of the intervention.~After the last blood extraction (3 h), an ad libitum lunch and 300 ml of water was provided. Volunteers ate until comfortably satisfied and the amount of food intake was registered
Study NCT02297074 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: 50 g of glucose were administered as a reference
Study NCT02235012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: KETAMINE PANPHARMA 250 mg/5mL, solution for infusion :~* Initial rapid infusion of 0,23 mg/kg~* Infusion from minute 2 to minute 30 : 0,00967 mg/kg/min~* Infusion from minute 31 to minute 120 : 0,00483 mg/kg/min
Study NCT02235012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: CHLORURE DE SODIUM 0,9 % MACOPHARMA :~* Initial rapid infusion of 0,23 mg/kg~* Infusion from minute 2 to minute 30 : 0,00967 mg/kg/min~* Infusion from minute 31 to minute 120 : 0,00483 mg/kg/min
Study NCT02263105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDDP
Study NCT03158623 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Study NCT04062331 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: By means of the magnetic stimulator we induce a cerebral electric current that is able to obtain a motor potential in the first dorsal interosseous bone of the left hand.~The intervention procedure consists of two steps: First step: Obtaining the Motor Evoked Threshold at Rest: Each patient, regardless of to the group to which they belong will have his/her threshold evoked motor calculated at rest, by stimulation of the right motor cortex, evoking electromyographic responses in the contralateral muscles. Second step: Administration of TMS: To calculate the motive threshold as the percentage of the same to which the treatment will have to be applied, a device equipped with a coil. The treatment will be administered for 5 consecutive days, with 3 weeks of rest, between each stimulation. To complete a treatment period of 14 months. The stimulation with TMS will be carried out every day in the same time slot for 5 consecutive days every 4 weeks, during a period of 14 months.
Study NCT02263105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: If hematologic and nonhematologic toxicity assessed according to the Common Terminology Criteria for Adverse Events (CTCAE; version 4.0) from the previous cycle had been grade 0 or 1, then TMZ dose escalation to was allowed to the maximum of 150 mg/m2. If grade 4 hematologic toxicity or grade 3 nonhematologic toxicity had occurred, then TMZ dose was reduced in 25 mg/m2 steps. If grade 4 nonhematologic toxicity occurred, patient treatment was halted. If grade 4 hematologic toxicity or grade 3 nonhematologic toxicity continued when TMZ dose was in the minimum of 75 mg/m2, patient treatment was halted.
Study NCT04383392 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rate adaptive pacing
Description: Rate-adaptive pacing is a function of permanent pacemaker to accelerate patients' heart rate when they are walking, stair climbing, running or carrying on intensive physical activity. Appropriately, the function is similar to human's electrophysiology of sinus node but it may be difficult to replace sinus node's function totally. For example, the acceleration or deceleration slope when exercise beginning or cessation is not always the same or consistent in different patients and different time.
Study NCT03158623 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cellerate
Study NCT00872378 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide
Description: Exenatide titrated up to 20mcg BID. (4 weeks at 5mcg BID; 4 weeks at 10mcg BID; 4 weeks at 15mcg BID; 37 weeks at 20mcg BID).
Study NCT00872378 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo titrated up to 20mcg BID. (4 weeks at 5mcg BID; 4 weeks at 10mcg BID; 4 weeks at 15mcg BID; 37 weeks at 20mcg BID).
Study NCT04383392 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rate adaptive pacing
Description: Rate-adaptive pacing is a function of permanent pacemaker to accelerate patients' heart rate when they are walking, stair climbing, running or carrying on intensive physical activity. Appropriately, the function is similar to human's electrophysiology of sinus node but it may be difficult to replace sinus node's function totally. For example, the acceleration or deceleration slope when exercise beginning or cessation is not always the same or consistent in different patients and different time.
Study NCT04325425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI Protocol
Description: Platinum-Etoposide regimen will be administered once every 21 days. Treatment will be continued for 6 to 8 cycles or 24 weeks maximum. One cycle consists of 21 days (3 weeks) with injection on D1 of each cycle (D1=D22). Patients are eligible for repeated treatment cycles in the absence of disease progression and undue adverse events.
Study NCT02125357 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Abiraterone acetate
Description: Abiraterone acetate 1000mg PO OD with prednisone 5mg PO BID or 10mg OD as per standard of care.
Study NCT02125357 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Enzalutamide
Description: 160mg PO OD as per standard of care.
Study NCT02570581 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Jelly with Alprazolam
Study NCT02279849 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communications
Description: Communication materials were used to promote healthier items to consumers in corner stores.
Study NCT02279849 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pricing
Description: The pricing incentives were used to help promote sales of healthier food items.
Study NCT02570581 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Oxazepam
Study NCT02570581 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Jelly with Oxazepam
Study NCT02279849 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined (Communications & Pricing)
Description: Communications with Pricing incentives were used to promote the sale/consumption of healthier foods.
Study NCT01567202 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Maximum resection of the tumor (≥95%) with the help of conventional or intraoperative MRI neuronavigation. Confirmation will be proceeded by the contrast MRI within 72 hours after surgery.
Study NCT01567202 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Surgery
Description: Maximum resection of the tumor (≥95%) with the help of conventional or intraoperative MRI neuronavigation. Confirmation will be proceeded by the contrast MRI within 72 hours after surgery.
Study NCT01567202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Temozolomide(TMZ), 200mg·m\^-2·d ×5 days，28 days every cycle. 6 cycles of TMZ are recommended.
Study NCT01567202 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chemotherapy
Description: Temozolomide(TMZ), 200mg·m\^-2·d ×5 days，28 days every cycle. 6 cycles of TMZ are recommended.
Study NCT01567202 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Standard dose, 4500 cGy to tumor with 3-cm margins, 1500 cGy boost to tumor bed.